Elutia Inc. (NASDAQ:ELUT) Stock Short Interest Jumps 119.6%

Elutia Inc. (NASDAQ:ELUT – Get Free Report) was the target of a large increase in short interest during the month of October. As of October 30th, there was short interest totaling 33,661 shares, an increase of 119.6% from the October 15th total of 15,326 shares. Based on an average daily trading volume, of 70,790 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.1% of the company’s stock are short sold.

Elutia Stock Performance

Elutia stock opened at $0.82 on Monday. The firm has a 50-day moving average of $0.82 and a 200-day moving average of $0.97. Elutia has a one year low of $0.50 and a one year high of $1.39. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.63 and a quick ratio of 2.61. The company has a market cap of $36.32 million, a price-to-earnings ratio of 0.74 and a beta of 0.93.

Elutia (NASDAQ:ELUT – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.11. The company had revenue of $1.14 million during the quarter, compared to analysts’ expectations of $1.00 million. Elutia had a negative return on equity of 140.53% and a net margin of 546.70%.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded Elutia from a “sell (d)” rating to a “sell (e+)” rating in a research report on Thursday, October 8th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Check Out Our Latest Analysis on ELUT

About Elutia

(Get Free Report)

Elutia is a medical technology company focused on developing biologic products for use in surgery. Its portfolio includes envelopes designed to support cardiac implantable electronic devices, such as pacemakers and defibrillators. The company’s products include CanGaroo, an extracellular-matrix envelope designed to help secure and support implanted devices, and EluPro, an antibiotic-eluting envelope intended to help reduce the risk of infection associated with these devices. Elutia was formerly known as Aziyo Biologics and adopted its current name in 2023 as it focused its business on drug-eluting biologic technologies.

See Also

Receive News & Ratings for Elutia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elutia and related companies with MarketBeat.com's FREE daily email newsletter.